Skip to main content
Premium Trial:

Request an Annual Quote

Maverix, Diagnomics Receive CLIA Validation for Aneuploidy Screening Test

NEW YORK (GenomeWeb) — Maverix Biomics and Diagnomics announced today that they have received CLIA validation for their next-generation sequencing pre-natal test on the Maverix Dx platform.

The test, called Non-Invasive Chromosome Examination (NICE), was developed by Diagnomics and the Eone-Diagnomics Genome Center, a joint venture between Diagnomics and the Eone Life Science Institute. It uses NGS to detect fetal chromosome aneuploidies in cell-free DNA, the companies said in a statement.

The test has been validated on Maverix's cloud-based NGS platform, which is also integrated with a laboratory information system for clinical and diagnostic testing.

"By achieving CLIA validation for NICE, we are further delivering on our promise to provide genomic sequencing and bioinformatics solutions that assist healthcare professionals worldwide in better understanding the genetic influence of personal health and disease," said Diagnomics President and EDGC CEO Min Seob Lee in a statement.

CLIA Director Philip Cotter, who administered the validation process, said the platform enabled molecular diagnostics testing efficiently and simply.